Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | ESRRB | O95718 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESRRA | P11474 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046244 | 0.91 | GPR119 (0.52) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL26580153 | 0.88 | GPR119 (0.67) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL1481563 | 0.84 | GPR119 (0.78) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL20046247 | 0.82 | GPR119 (0.47) | GPR119KMT2AMEN1MAPTLMNA | |
| SCHEMBL29986023 | 0.81 | MAPT (0.76) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL20046841 | 0.81 | GPR119 (0.57) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL5238945 | 0.79 | GPR119 (0.71) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL22873407 | 0.79 | GPR119 (0.54) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL3486856 | 0.78 | GPR119 (1.00) | GPR119KMT2AMEN1MAPTALDH1A1 | |
| SCHEMBL8348627 | 0.78 | GPR119 (0.62) | GPR119KMT2AMEN1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | GPR119 887/4885KMT2A 1463/4885MEN1 1674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.